

**CONSULTING / SERVICES AGREEMENT**  
**WITH (A) PATIENT, (B) PATIENT ADVOCATE,**  
**OR (C) PATIENT ADVOCACY GROUP**

This Agreement (the "**Agreement**") is made on 1<sup>st</sup> April, 2026 between,

SANOFI A/S, a company duly organized under the laws of Denmark under the business identity number 19064301 and having its registered office located at Vibenshuset, Lyngbyvej 2, 2100 København Ø - Denmark ("**Sanofi**")

and

Anne Vastrup, Eksemlforeningen, Hvidovrevej 108, 1. tv, 2650 Hvidovre (the "**Service Provider**")

**NOW THEREFORE**, the Parties agree as follows:

- 1. Services.** The Service Provider will provide the services described in Exhibit A (the "**Services**").
- 2. Compensation.**
  - 2.1 Service Fee.** Sanofi will pay to the Service Provider a compensation for the Services provided as specified in Exhibit B (the "**Service Fee**"), which to the best of their knowledge, constitutes fair market value for the Services.
  - 2.3 Expenses.** Sanofi will also pay or reimburse all reasonable and necessary expenses incurred by the Service Provider relating directly to the performance of the Services and in accordance with Exhibit B (the "**Expenses**").
  - 2.4 Invoice.** Service Provider will invoice Sanofi for the Service Fee and any reimbursable expenses by sending an invoice to the address and details specified in Exhibit B, which will be paid by Sanofi in the following 30 days.
- 3. Independent Contractor**
  - 3.1 Relationship.** Service Provider will perform the Services as an independent contractor and not as an employee of Sanofi.
  - 3.2 Taxes.** Service Provider will comply with all social and tax obligations relating to the performance of the Services and make the necessary tax declarations and payments.
  - 3.3 Injury and Damages.** Sanofi will not be responsible for any damages suffered by the Service Provider in the execution of this Agreement.

3.4 **Transparency.** The Service Provider will disclose his/her consulting relationship with Sanofi whenever he/she writes or speaks in public about an issue relating to the Services.

#### 4. **Confidentiality, Transparency and Results**

4.1 **Confidentiality.** For the next 5 years you shall maintain as confidential and shall not disclose to a third party, nor use for purposes other than the performance of this Agreement, any information which relates to Sanofi's or its affiliated companies' business affairs, including research and development activities and the terms of this Agreement or other confidential or proprietary information (hereinafter "**Confidential Information**"). You will also prevent the unauthorized, negligent, or inadvertent use, disclosure, or publication of Sanofi Confidential Information.

4.3 **Transparency – Financial Disclosure.** When required by applicable laws, certain information related to the Agreement (for example, the names of the Parties, the remuneration (including fees and expenses reimbursed) as well as the title and purpose of the Agreement) may be communicated to relevant authorities and/or be publicly disclosed by Sanofi and/or by its affiliates.

#### 5. **Data Protection**

5.1 **Personal Data Protection.** To the extent required, both Parties shall, with respect to their own files containing personal data, (i) complete the required formalities with the relevant regulator(s); (ii) inform individuals whose personal data are collected of their rights pursuant to the relevant laws and obtain their consent in writing, as needed according to applicable data privacy laws; and (iii) take all measures necessary to preserve the security and confidentiality of personal data to prevent it from being distorted, damaged or accessed by unauthorized Third Parties.

5.2. **Lawfulness and Fairness of Personal Data Processing.** Service Provider declares that patients' personal data has been collected in a fair and lawful way and that patients whose contact details will be transferred to Sanofi are informed of this transfer and they don't object to it.

6. **Term.** This Agreement will start on April 1, 2026 and terminate on completion of the Services.

7. **Governing Law and Disputes.** This Agreement shall be governed by and construed in accordance with the laws of Belgium and any disputes arising out of or related to this Agreement, which cannot be settled amicably between the Parties, shall be submitted to the exclusive jurisdiction of the competent court of Belgium.

**SANOFI**

Signature: Rama Pryce  
Rama Pryce (02/04/2026 08:44:19 GMT+2)

---

Name: Rama Pryce

---

Title: Patient Engagement Lead  
North Europe  
Sanofi

---

**SERVICE PROVIDER**

Signature: Anne Skov Vastrup  
Anne Skov Vastrup (05/04/2026 09:26:08 GMT+2)

---

Name: Anne Vastrup

---

Title: Forperson,  
Eksemforeningen

---

**EXHIBIT A – SERVICES**

<b>Engagement Name</b>	Type 2 patient survey
<b>Engagement type</b>	Consultancy on the development of the: patient questionnaire and the messaging in relation to the SoMe reach out, the breakdown of data and key findings and qualifying the final awareness report.
<b>Description of the Services:</b>	<p>Sanofi is developing an international patient survey focusing on life with multiple Type 2 inflammatory diseases, including atopic dermatitis, PN, asthma, nasal polyps, allergies, and more.</p> <p>The purpose of the survey is to generate new insights into:</p> <ul style="list-style-type: none"> <li>• The disease burden among people living with several Type 2 diseases simultaneously</li> <li>• The everyday challenges that arise when these conditions overlap</li> <li>• The barriers patients face in healthcare systems that are often experienced as fragmented and siloed</li> </ul> <p>The survey will be conducted in Denmark, Norway, Sweden, Finland, the Netherlands, and Belgium.</p> <p>Our ambition is to have a survey report ready by Q4 2026, with the aim of publishing an awareness report.</p> <p>We intend to disseminate the findings widely and raise awareness among patients, healthcare professionals, and—ideally—policy makers. The ambition is to increase awareness.</p>
<b>Deliverable(s)</b>	<p>The deliverables - consultancy and qualification of:</p> <ol style="list-style-type: none"> <li>1) The patient questionnaire and the messaging in relation to the SoMe reach out.</li> <li>2) The breakdown of data and key findings.</li> <li>3) Qualifying the final awareness report.</li> </ol> <p>It is estimated that 5 hours will be used on the engagement</p>
<b>Meeting date(s)</b>	<p>First round of feedback will be delivered in writing before April 12. 2026.</p> <p>Second round of feedback will be given in Q2 2026 when data is in place</p> <p>Third round of feedback is scheduled to take place in Q4 in relation to the finalization of the awareness report</p>
<b>Venue</b>	All engagements are digital.

## **EXHIBIT B - FINANCIAL TERMS**

### **Service Fee**

Anne Vastrup and Eksemforeningen will not be receiving payment for their involvement in the project.

### **Travel and Accommodation Expenses**

If applicable, travel and lodging for Service Provider's attendance of meetings will be booked and paid for by Sanofi.

Alternatively, Sanofi will reimburse Service Provider for travel and lodging booked and paid for by Service Provider, provided that Sanofi's authorized representative for the Agreement, Rama Pryce, rama.pryce@sanofi.com, approved the expenses in writing beforehand.

Sanofi will reimburse Service Provider for agreed to expenses upon receipt of the original receipts.

Sanofi shall not pay for upgrades or for any travel or subsistence expenses for spouses or other traveling companions.

### **Hotel / Airline Travel Expenses**

- Hotel accommodation will be modest (hotel rating shall not exceed 4 stars).
- All expenses in addition to the room rate and breakfast are at Service Provider's expense, e.g. expenses related to the use of pay-tv, mini-bar, bar and telephone.
- Airline travel within Europe will be in economy class. Transatlantic or long-distance airline travel (i.e. more than six consecutive flight hours) will be in business class.
- If Service Provider is combining travel or overnight stays with other business-related or personal travel, Sanofi will only cover the appropriate portion of the travel itinerary and hotel accommodation.
- Public transport (bus, subway, first class train travel), taxi and/or parking costs will be reimbursed at full rate. This is subject to Sanofi receiving the receipts or tickets for the expenses incurred.

### **Invoicing and Payment**

Please send your invoice to: pia.tolman@sanofi.com

Sanofi